Executive Summary
The two filings in this stream highlight a deeply distressed corporate landscape in the US, with both companies undergoing Chapter 11 bankruptcy proceedings. Synergy CHC Corp. filed for Chapter 11 on September 4, 2026, triggering a complete board overhaul and appointment of a Chief Restructuring Officer, signaling a likely liquidation or major reorganization.
Sangamo Therapeutics, in its first monthly operating report post-petition, reveals a cash burn of $11.2 million in July 2026, with total liabilities of $97.1 million against $16.9 million cash, indicating a precarious liquidity position. Both companies exhibit negative sentiment and high materiality, with no positive forward-looking indicators. The lack of any period-over-period revenue or margin data in these filings suggests a focus on survival rather than operational performance. The sector theme is one of acute financial distress, with governance instability and rapid cash depletion as key risk factors.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US Bankruptcy Chapter 11 Insolvency SEC Filings digest from September 02, 2026.
Investment Signals (8)
- Synergy CHC Corp. ↓ (BEARISH)▲
Chapter 11 filing on September 4, 2026, with intent to file a plan of liquidation or reorganization within 120 days; four directors resigned, including the President, leaving a single director, indicating a potential complete exit from current operations
- Synergy CHC Corp. ↓ (BEARISH)▲
Appointment of Lauren P. Berret as Chief Restructuring Officer (effective Aug 26, 2026) signals a formalized restructuring process, but also confirms the company's inability to continue as a going concern without court protection
- Sangamo Therapeutics ↓ (BEARISH)▲
Cash position of $16.9M at July 31, 2026, with a monthly loss of $11.2M, implying a cash runway of only ~1.5 months unless additional financing or asset sales occur
- Sangamo Therapeutics ↓ (BEARISH)▲
Postpetition debt of $19.0M exceeds cash on hand, indicating a negative net cash position and high reliance on debtor-in-possession financing or asset monetization
- Sangamo Therapeutics ↓ (BEARISH)▲
Reorganization items of $4.2M in July alone represent 38% of the monthly loss, highlighting the cost burden of the bankruptcy process
-
No assets sold or transferred outside the ordinary course of business in July, suggesting no immediate liquidity infusion from asset sales [NEUTRAL/BEARISH]
- Synergy CHC Corp. ↓ (NEUTRAL)▲
The resignations were not due to disagreements, which may reduce the risk of litigation but does not mitigate the fundamental insolvency
- Sangamo Therapeutics ↓ (NEUTRAL)▲
Postpetition taxes past due of $0 indicates compliance with tax obligations, a minor positive in an otherwise negative picture
Risk Flags (7)
- Synergy CHC Corp./Governance↓ [HIGH RISK]▼
Four directors resigned, including the President, leaving a single director; this creates a governance vacuum and potential for operational paralysis
- Synergy CHC Corp./Liquidation↓ [HIGH RISK]▼
The company intends to file a plan of liquidation or reorganization within 120 days, but the lack of detail on assets or going-concern value raises the risk of a full liquidation with minimal recovery for stakeholders
- Sangamo Therapeutics/Cash Burn↓ [HIGH RISK]▼
Monthly loss of $11.2M against $16.9M cash implies a cash runway of less than 2 months, risking an emergency sale or further dilution
- Sangamo Therapeutics/Liquidity↓ [HIGH RISK]▼
Postpetition debt of $19.0M exceeds cash, indicating a negative working capital position and potential for creditor disputes
- Sangamo Therapeutics/Reorganization Costs↓ [MEDIUM RISK]▼
$4.2M in reorganization items in one month suggests escalating professional fees, which could consume a significant portion of the estate's value
- Sangamo Therapeutics/No Asset Sales↓ [MEDIUM RISK]▼
The absence of asset sales in July indicates a lack of immediate monetization strategy, prolonging the cash burn
- Both Companies/Market Sentiment [MEDIUM RISK]▼
Both filings carry negative sentiment, which could lead to further sell-offs in the stocks and widening credit spreads
Opportunities (6)
- Sangamo Therapeutics/Asset Sale↓ (OPPORTUNITY)◆
The company has $155.1M in total assets against $97.1M liabilities, suggesting potential for asset sales to generate liquidity; monitor for any sale announcements in upcoming monthly operating reports
- Sangamo Therapeutics/Reorganization Plan↓ (OPPORTUNITY)◆
The Chapter 11 process may allow for a debt-for-equity swap or a sale of the business as a going concern, offering potential upside for distressed investors if the underlying technology or pipeline has value
- Synergy CHC Corp./Liquidation Value↓ (OPPORTUNITY)◆
The company's plan to file a liquidation plan may reveal hidden asset value; investors with a high risk tolerance could speculate on the recovery value
- Sangamo Therapeutics/Postpetition Financing↓ (OPPORTUNITY)◆
The company may secure debtor-in-possession financing, which could provide a lifeline and extend the runway, creating a potential catalyst for the stock
- Sangamo Therapeutics/Operational Efficiency↓ (OPPORTUNITY)◆
The monthly operating report will provide ongoing transparency; a reduction in monthly losses in subsequent reports could signal successful cost-cutting
- Synergy CHC Corp./Restructuring Expertise↓ (OPPORTUNITY)◆
The engagement of a Chief Restructuring Officer and specialized counsel suggests a professional approach, which may lead to a more favorable outcome for creditors and possibly equity holders
Sector Themes (5)
- Bankruptcy Wave in US◆
Two Chapter 11 filings within the same stream period indicate a broader trend of corporate distress, potentially driven by high interest rates and tightening credit conditions [IMPLICATION: Increased risk of defaults across sectors]
- Governance Instability◆
Both companies experienced significant board changes (Synergy CHC) or are under court supervision (Sangamo), highlighting the governance challenges that accompany insolvency [IMPLICATION: Investors should monitor board composition as a leading indicator of distress]
- Cash Burn vs. Asset Value◆
Sangamo's $11.2M monthly burn against $155.1M assets shows that asset-rich companies can still face liquidity crises, underscoring the importance of cash flow over book value [IMPLICATION: Focus on cash runway and burn rates in distressed analysis]
- Reorganization Costs◆
The $4.2M in reorganization items at Sangamo illustrates the high cost of bankruptcy, which can erode value for stakeholders [IMPLICATION: Professional fees are a significant drag in Chapter 11 cases]
- No Positive Guidance◆
Neither filing provided any forward-looking revenue or earnings guidance, reflecting the uncertainty and lack of visibility in distressed situations [IMPLICATION: Investors should avoid relying on traditional valuation metrics for these companies]
Watch List (6)
-
Plan of liquidation or reorganization due within 120 days (by ~Jan 2, 2027); watch for details on asset sales and creditor recoveries
-
Next monthly operating report expected in early October 2026; monitor for changes in cash position and any asset sale announcements
-
Watch for any motions to sell assets or obtain debtor-in-possession financing in the bankruptcy court docket
-
Court hearings on the bankruptcy case; monitor for any objections to the plan or motions to convert to Chapter 7
-
Potential hearings on the adequacy of disclosure statements or plan confirmation; watch for any proposed reorganization plan
- Both Companies👁
Monitor for any insider trading activity (e.g., sales of stock or options) that might signal management's view on recovery prospects
Filing Analyses
(2)
08-09-2026
Synergy CHC Corp. (SNYR) filed for Chapter 11 bankruptcy on September 4, 2026, in the U.S. Bankruptcy Court for the District of Columbia (Case No. 26-465-ELG). The company intends to file a plan of liquidation or reorganization within 120 days. In connection with the filing, four directors (Alfred Baumeler, Nitin Kaushal, J. Paul SoRelle, Teresa Thompson) resigned, and Alfred Baumeler also resigned as President; Jack Ross remains the sole director. Lauren P. Berret of Eisner Advisory Group LLC was engaged as chief restructuring officer effective August 26, 2026.
- · The bankruptcy case is captioned In re Synergy CHC Corp., Case No. 26-465-ELG, in the United States Bankruptcy Court for the District of Columbia.
- · The company has engaged The VerStandig Law Firm, LLC as counsel and advisor in connection with the bankruptcy case.
- · The resignations of the four directors were not the result of any disagreement with the company regarding operations, policies, or practices.
- · Alfred Baumeler's resignation as President was effective August 31, 2026.
- · The company's common stock trades on Nasdaq under the symbol SNYR.
08-09-2026
Sangamo Therapeutics, Inc. reported its first monthly operating report after commencing Chapter 11 proceedings on June 23, 2026, with $16,906,955 of cash at July 31, 2026, $155,117,944 of total assets and $97,132,393 of total liabilities. The company recorded a current-month loss of $11,165,298, including $4,244,225 of reorganization items, while postpetition debt totaled $19,038,048; however, no assets were sold or transferred outside the ordinary course of business and postpetition taxes past due were $0.
- · The voluntary Chapter 11 petition was filed on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware.
- · The reporting period covered July 1, 2026 through July 31, 2026.
- · The monthly operating report was signed by Nikunj Jain on September 2, 2026.
- · The report was prepared on an accrual basis and stated that it was unaudited and not prepared in accordance with U.S. GAAP.
- · Accounts receivable over 90 days outstanding were $90,355, representing approximately 18.07% of total accounts receivable.
- · Postpetition payables past due of $366,473 represented approximately 1.95% of postpetition payables excluding taxes.
- · The company reported $0 of inventory.
- · The industry classification was 3254.
- · No postpetition income taxes were accrued or paid, and no postpetition property taxes were paid.
Get daily alerts with 8 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 2 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Bankruptcy Chapter 11 Insolvency SEC Filings
August 28, 2026
US Bankruptcy Chapter 11 Insolvency SEC Filings — August 28, 2026
August 24, 2026
US Bankruptcy Chapter 11 Insolvency SEC Filings — August 24, 2026
July 24, 2026
US Bankruptcy Chapter 11 Insolvency SEC Filings — July 24, 2026
July 20, 2026
US Bankruptcy Chapter 11 Insolvency SEC Filings — July 20, 2026
🇺🇸 More from United States
View all →September 14, 2026
US Pre-Market SEC Filings Roundup — September 14, 2026
US Pre-Market SEC Filings Roundup
September 14, 2026
US Merger & Acquisition SEC Filings — September 14, 2026
US Merger & Acquisition SEC Filings
September 14, 2026
USA Insider Trading Pulse — September 14, 2026
USA Insider Trading Pulse
September 13, 2026
General Federal Contracts — September 13, 2026
General Federal Contracts